Panelists discusses how bronchiectasis differs from other respiratory diseases like asthma and COPD through symptoms, imaging findings, and pathophysiological mechanisms. Bronchiectasis is ...
Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help ...
The Medicines and Healthcare products Regulatory Agency has granted marketing authorisation for brensocatib, branded as ...
MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...
Brensocatib is the first medicine of its kind to be approved in the UK for preventing flare‑ups in NCFB. It works by blocking ...
Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. This is a video synopsis/summary of an ...
Milan, Italy: The colour of the phlegm from patients with the lung disease bronchiectasis can indicate the degree of inflammation in their lungs and predict their future outcomes, according to new ...
For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results